Woodmont Investment Counsel LLC lifted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,491 shares of the company’s stock after acquiring an additional 305 shares during the period. Johnson & Johnson accounts for approximately 1.4% of Woodmont Investment Counsel LLC’s holdings, making the stock its 14th biggest position. Woodmont Investment Counsel LLC’s holdings in Johnson & Johnson were worth $12,806,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in JNJ. Vanguard Group Inc. lifted its stake in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares during the last quarter. State Street Corp lifted its stake in Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after purchasing an additional 803,013 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock valued at $4,154,022,000 after purchasing an additional 805,831 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after acquiring an additional 328,297 shares during the period. Finally, California Public Employees Retirement System raised its holdings in shares of Johnson & Johnson by 2.7% during the third quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock valued at $1,919,726,000 after acquiring an additional 310,473 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Stock Performance
JNJ stock opened at $162.69 on Friday. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The firm has a 50 day moving average of $157.48 and a two-hundred day moving average of $166.96. The company has a market capitalization of $423.69 billion, a price-to-earnings ratio of 34.04, a P/E/G ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $186.69.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.93%. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is currently 94.56%.
Insider Buying and Selling
In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.20% of the stock is owned by insiders.
Wall Street Analyst Weigh In
JNJ has been the topic of a number of recent analyst reports. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Atlantic Securities cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday. SVB Leerink cut their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $173.00.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- No, It Isn’t Time To Sell IBM Stock
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
